Interviews: Biomunex CSO defines lead compounds, early R&D plans

Interviews: Biomunex CEO on earlier deals for cancer drugs

Interviews: Bispecific Antibodies Close in on Cancer (GEN EXLUSIVES)

Press Release: nomination of Dr. Amigorena and Dr. Grabulovski as Key Advisers

Press Release: Biomunex presents novel data on BiXAb® antibodies

Press Release: nomination of the CSO Dr. Zhukovsky